Physician profile
Sawsan Amireh
NPI 1548652514
$1,088.95
in general payments reported to CMS, 2019-2025
18 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $169 · 2021: $56.94 · 2022: $55.19 · 2023: $244 · 2024: $160 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.14 |
| Education | $109.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $220.50 | 2019-2020 | |
| Pfizer INC. | $140.78 | 2019-2025 | |
| Incyte Corporation | $108.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $94.12 | 2023-2025 | |
| Exelixis INC. | $79.00 | 2023 | |
| Celgene Corporation | $73.69 | 2019-2023 | |
| Astellas Pharma US INC | $49.28 | 2022-2024 | Padcev |
| Amgen INC. | $49.26 | 2020-2024 | Prolia, Evenity |
| Pharmacosmos Therapeutics INC. | $43.34 | 2023 | Monoferric |
| Daiichi Sankyo INC. | $40.99 | 2021-2022 | |
| Puma Biotechnology, INC. | $39.48 | 2019 | |
| Janssen Biotech, INC. | $34.23 | 2024 | Rybrevant |
| Stemline Therapeutics INC. | $24.29 | 2025 | Orserdu |
| Genzyme Corporation | $22.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.68 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $18.35 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.40 | 2021 | |
| Merck Sharp & Dohme LLC | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sawsan Amireh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.